TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03396146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 ml total blood tubes volume
Description: 12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 ml total blood tubes volume
Description: 12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 ml total blood tubes volume
Description: 12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal sample
Description: Fecal sample at inclusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal sample
Description: Fecal sample at inclusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal sample
Description: Fecal sample at inclusion
Study: NCT02772263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHAP-EMS
Description: The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
Study: NCT00030238

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium supplement
Description: Calcium Carbonate capsules prepared by NIH PDS

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
Study: NCT04439747

Intervention type: OTHER
Intervention: Ultrasound, DXA, hormonal tests
Description: Diagnostic tests in selected groups with investigation of revealed hormonal disorders

Intervention type: OTHER
Intervention: Ultrasound, DXA, hormonal tests
Description: Diagnostic tests in selected groups with investigation of revealed hormonal disorders

Intervention type: OTHER
Intervention: Ultrasound, DXA, hormonal tests
Description: Diagnostic tests in selected groups with investigation of revealed hormonal disorders
Study: NCT01317446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amine fluoride/stannous fluoride
Description: 10 ml qd, oral, topical, 6 months duration
Study: NCT00019747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: adjuvant therapy
Description: Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily
Study: NCT00743444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 65 mg capsules, oral, 3 single doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, 3 single doses
Study: NCT00003005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cordycepin
Description: Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycoformycin
Description: Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
Study: NCT00310726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abrupt weaning at 4 months
Description: abrupt weaning at 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued exclusive breastfeeding
Description: Continued exclusive breastfeeding
Study: NCT03168048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: Oncologic therapy support by means of a mobile application
Study: NCT01426295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate de sodium
Description: Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®.
Study: NCT03203538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-light, 1000 lux
Description: Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED-light, 100 lux
Description: Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-light, 7000 K
Description: Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
Study: NCT03993249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: standard of care chemoradiotherapy + Nivolumab

Intervention type: OTHER
Group type: OTHER
Intervention: chemoradiotherapy
Description: standard of care chemoradiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: standard of care chemoradiotherapy
Study: NCT05362721

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure-volume loop catheter
Description: The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
Study: NCT01797484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Improvement of myocardial microcirculation
Study: NCT03452774

Intervention type: OTHER
Intervention: Clinical Trial Matching
Description: Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
Study: NCT03533582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT03203538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED-light, 2500 K
Description: Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LED-light
Description: Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
Study: NCT03533582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03477604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroStent and Standard PTA
Description: Self-expanding stent and standard PTA balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA
Description: Standard PTA balloon
Study: NCT03784248

Intervention type: OTHER
Intervention: blood donation and isolation of leuco-platelet layers
Description: patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice

Intervention type: OTHER
Intervention: blood donation and isolation of leuco-platelet layers
Description: patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
Study: NCT04275726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myval THV Series
Description: The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contemporary Valves (Sapien THV Series and Evolut THV Series)
Description: The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
Study: NCT01953328

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study: NCT00133900

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Peripheral blood draws for evaluation of circulating tumor cells
Study: NCT03924141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in de-escalation
Description: Will receive one hour of de-escalation training
Study: NCT01760941

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
Study: NCT03062007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-CON-02
Description: BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
Study: NCT02867150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ward Photonics Photonica Professional
Description: Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy.
Study: NCT01136369

Intervention type: DEVICE
Intervention: OSNA Breast Cancer System
Description: For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required.
Study: NCT02916316

Intervention type: DRUG
Intervention: R-CHOP with doxorubicin
Description: Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
Study: NCT03203538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red LED-light
Description: Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
Study: NCT02461836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Protocol: 5 Gy/d, for 5 consecutive days
Study: NCT02541474

Intervention type: OTHER
Group type: OTHER
Intervention: Integrated care
Description: The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
Study: NCT00311181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
Description: Patients that are indicated for an ICD or CRT-D receive one of these devices.
Study: NCT01378936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI plus IOC group intervention
Description: 45 minute Motivational Interview plus 16 session IOC intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview only
Description: 45 minute Motivational Interview session
Study: NCT01159626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 20 mg dose as two 10mg controlled release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 40 mg dose as four 10mg controlled release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 60 mg dose as six 10mg controlled release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single dose as matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral multiple doses as matching placebo for 7 days
Study: NCT04050501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive Vagus Nerve Stimulator
Description: Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
Study: NCT03120481

Intervention type: OTHER
Intervention: no intervation
Description: no intervention
Study: NCT03258047

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
Study: NCT02450344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive health promotion
Description: An Internet quiz game competition utilising quiz questions related to alcohol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive health promotion
Description: An electronic package of information related to alcohol
Study: NCT01549756

Intervention type: BEHAVIORAL
Intervention: bulletin board and teleophone depth interview
Description: qualitative based research
Study: NCT00807144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Kidney transplant maintenance immunosuppression)
Description: Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
Study: NCT02776813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT04039919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study: NCT02117102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder and lumbar stimulation technic
Study: NCT04039919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study: NCT03735732

Intervention type: BEHAVIORAL
Intervention: prime
Description: groups be confronted with health or palatability aspects of food items
Study: NCT03585387

Intervention type: PROCEDURE
Intervention: Navigation
Description: Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
Study: NCT01343472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISP supervision
Description: WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
Study: NCT04039919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PSL)
Description: Placebo will be provided matching Padsevonil to maintain the blinding.
Study: NCT01343472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole-as-usual
Description: Parolees are supervised under standard parole supervision practice in Washington State.
Study: NCT02050841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octaplas
Description: Octaplas S/D Plasma
Study: NCT02865174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
Study: NCT02590107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Plus
Description: Receive nutritional supplementation twice daily to provide 28g of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Stat 101
Description: Receive nutritional supplementation twice daily to provide 30g of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milkshake
Description: Receive alternate nutritional supplementation once daily to provide 28g protein
Study: NCT00402220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Active Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial Magnetic Stimulation
Study: NCT02324673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT03197558

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Tymbion Iontophoresis and Tube Delivery System (TDS)
Description: Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
Study: NCT02280226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging (MRI)